Skip to main content


Latest articles

16-12-2020 | Rheumatology | News | Article

Patients with rheumatic diseases may not have elevated COVID-19 mortality risk

Findings from two studies published in the Annals of the Rheumatic Diseases suggest that people with rheumatic diseases may not have a higher risk for COVID-19 mortality and other adverse outcomes than those without.

15-12-2020 | Rheumatology | News | Article

ACTT-2 trial: Baricitinib shows promise for COVID-19

Adding the JAK inhibitor baricitinib to remdesivir treatment reduces recovery time and improves clinical outcomes in hospitalized patients with moderate-to-severe COVID-19, suggest findings from the ACTT-2 randomized controlled trial.

14-12-2020 | Rheumatology | News | Article

RA linked to increased pancreatitis risk

People with rheumatoid arthritis have an increased risk for developing pancreatitis and pancreatic cancer compared with the general population, US study data show.

11-12-2020 | Rheumatology | News | Article

Modifying obesity key to gout prevention

Research suggests that around three-quarters of incident gout cases could be prevented by modifying weight, diet, use of diuretics, and alcohol consumption.

10-12-2020 | Rheumatology | News | Article

Combining QRISK3 and EULAR mSCORE may optimize CV risk prediction in RA

Combining the QRISK3 and the EULAR modified systematic coronary risk evaluation algorithms may optimize identification of people with rheumatoid arthritis at high risk for carotid plaques, research suggests.

09-12-2020 | Rheumatology | News | Article

Early response to RA treatment may predict sustained DMARD-free remission

In patients with ACPA-negative rheumatoid arthritis, research suggests that an early response to treatment increases the likelihood of reaching sustained DMARD-free remission.

08-12-2020 | Rheumatology | News | Article

IL-6 ‘not a relevant therapeutic target’ in primary Sjögren’s syndrome

Treatment with the IL-6 receptor inhibitor tocilizumab does not improve clinical outcomes for patients with primary Sjögren’s syndrome, suggest findings from the ETAP trial.

07-12-2020 | Rheumatology | News | Article

axSpA disease activity longitudinally associated with disability

Disease activity has the strongest impact on disability over time in people with early axSpA, study findings indicate.

04-12-2020 | Rheumatology | News | Article

Even low-dose oral glucocorticoid use associated with increased CV risk

UK research has identified a “strong dose-dependent” association between oral glucocorticoid use and CVD risk among people with immune-mediated diseases, with an increased risk seen even at doses of less than 5 mg/day.

03-12-2020 | Rheumatology | News | Article

Guselkumab approved for psoriatic arthritis in Europe

Click through for additional information on this expanded indication

02-12-2020 | Rheumatology | News | Article

Meta-analysis confirms elevated infection risk in SLE

Patients with systemic lupus erythematosus are at greater risk for infections than the general population, shows a meta-analysis.

01-12-2020 | Rheumatology | News | Article

3-year results support long-term efficacy of baricitinib in RA

Patients with moderate-to-severe rheumatoid arthritis treated with the JAK inhibitor baricitinib experience benefits for up to 3 years, researchers report.

30-11-2020 | Rheumatology | News | Article

Subcutaneous delivery feasible for anifrolumab in SLE

Phase 2 study data suggest that subcutaneous administration is a feasible option for treatment with the type I interferon receptor inhibitor anifrolumab in patients with systemic lupus erythematosus.

27-11-2020 | Rheumatology | News | Article

No clinical benefit of abatacept in primary Sjögren’s syndrome

Phase 3 trial results indicate that abatacept does not have significant clinical efficacy in patients with moderate-to-severe active primary Sjögren’s syndrome.

26-11-2020 | Rheumatology | News | Article

Further evidence against hydroxychloroquine use for prevention, treatment of COVID-19

Findings from two randomized trials provide further evidence to suggest that hydroxychloroquine has no benefits for the prevention or treatment of COVID-19.

25-11-2020 | Rheumatology | News | Article

Methotrexate discontinuation may be feasible in PsA patients treated with tofacitinib

Patients with psoriatic arthritis undergoing stable treatment with tofacitinib plus methotrexate may be able to withdraw methotrexate without having an adverse impact on disease activity, suggests a substudy of the OPAL Balance trial.

24-11-2020 | Rheumatology | News | Article

NSAIDs unlikely to increase COVID-19 susceptibility in people with osteoarthritis

Among patients with osteoarthritis, the risk for COVID-19 is not increased with the use of NSAIDs versus comparator analgesics, study findings indicate.

23-11-2020 | Rheumatology | News | Article

No reduction in COVID-19 mortality risk with routine hydroxychloroquine use in RMD patients

Use of hydroxychloroquine for the treatment of rheumatic and musculoskeletal diseases is not associated with a reduction in COVID-19 mortality risk, suggest findings from an observational study published in The Lancet Rheumatology.

20-11-2020 | Rheumatology | News | Article

FDA authorizes baricitinib combination for COVID-19

Click through for more information on this Emergency Use Authorization

19-11-2020 | Rheumatology | News | Article

Intensive acupuncture may improve pain, function in knee osteoarthritis

An 8-week intensive course of electro-acupuncture could improve pain and function in patients with knee osteoarthritis, with the effects lasting for up to 26 weeks, Chinese research shows.

Image Credits